Status:
UNKNOWN
Concordance Between Buccal Cavity Swab and Nasopharyngeal Swab for SARS-CoV-2 (COVID-19) Detection by RT-PCR and ELISA
Lead Sponsor:
Datar Cancer Genetics Limited
Collaborating Sponsors:
Test At Home Pte. Ltd
National University of Singapore
Conditions:
Covid19
Eligibility:
All Genders
18-70 years
Brief Summary
Nasopharyngeal Swabs (NPS) used to test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection can cause mild to severe discomfort in addition to increasing the risk of transmissio...
Detailed Description
Nasopharyngeal Swabs (NPS) are used to test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. For this, a swab is inserted deep into the back of the nose to collect a sample....
Eligibility Criteria
Inclusion
- Males and Females
- Adults
- Known COVID-19 positive by RTPCR (with active infection) OR Known COVID-19 negative by RTPCR (tested within 7 days)
- Provision of Informed Consent
- Willing to provide Nasopharyngeal Swab as well as Buccal Cavity Swab
Exclusion
- Pediatric patients.
- Inability to provide Informed Consent.
- Inability to provide Nasopharyngeal Swab and / or Buccal Cavity Swab.
Key Trial Info
Start Date :
March 31 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04732637
Start Date
March 31 2021
End Date
August 31 2021
Last Update
March 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Datar Cancer Genetics
Nashik, Maharashtra, India, 422010